SciELO - Scientific Electronic Library Online

 
vol.46 número1Evaluación de la relación exposición-respuesta de cetuximab en pacientes con cáncer colorrectal metastásico y cáncer de cabeza y cuelloAplicación de las ciclodextrinas como excipientes en productos farmacéuticos: ¿por qué no en formulación magistral? índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Farmacia Hospitalaria

versión On-line ISSN 2171-8695versión impresa ISSN 1130-6343

Resumen

SAROBE, Maite; ARRONDO, Amaya; IBARRONDO, Oliver  y  MAR, Javier. Health-related quality of life in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis treated with certolizumab pegol. Farm Hosp. [online]. 2022, vol.46, n.1, pp.27-30.  Epub 12-Sep-2022. ISSN 2171-8695.  https://dx.doi.org/10.7399/fh.11638.

Objective:

Inflammatory joint diseases cause pain and disability. The objective of this study was to measure the quality of life of patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis treated with certolizumab pegol and compare the results with those of the general population.

Method:

Using a cross-sectional design and sociodemographic and clinical variables, adherence to treatment and quality of life data were collected using the Euroqol-5d-5L (EQ-5D) questionnaire. The quality of life of the general population was obtained from the Spanish National Health Survey. Answers to the EQ-5D questionnaire were analyzed in both groups using two-part models, which measure the probability of having perfect health as well as the disutility caused by the disease.

Results:

The sample included 59 patients with high adherence (92.3%). The mean utility value was 0.78 and pain was the most affected dimension. The reduction in utility (EQ-5D index) of patients with inflammatory joint disease as compared to the general population was 0.127.

Conclusions:

The subjects of the study showed a significantly lower quality of life than the general population despite effective control of the disease. Two-part models facilitate the interpretation of quality-of-life studies using the EQ-5D.

Palabras clave : Health-related quality of life; Medication adherence; Certolizumab pegol; Patient-reported outcome measures; Arthritis, rheumatoid; Arthritis, psoriatic; Spondylitis, ankylosing.

        · resumen en Español     · texto en Español     · Español ( pdf )